Outcomes4Me Secures $21M in Funding Learn more >>

Patient Login
Patient Sign Up
Log out
Go to Patient Dashboard
Go to Dashboard
Patient Login
Patient Sign Up
Log out
Go to Patient Dashboard
Go to Dashboard
/ Cancer Resources

Cancer Blog and Resources

Articles

For Patients
For Oncology Care Providers
For Life Sciences
close up of doctor and patients hands

Enhertu for HER2-positive cancer: How it works and side effects explained

What you should know about Enhertu We had the honor of hosting medical oncologist Dr....
older man using phone next to window sitting down

From novel drug therapies to AI: the latest in prostate cancer care

Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting gathers oncologists from around...
Mammogram procedure in medical clinic, mammography. Female mammologist positions mature woman at imaging machine to receive mammogram

When to start mammograms: Screening advice from Dr. Amy Kelly

Breast imaging is a complex topic that can be difficult to navigate. We had the...
doctor consulting older woman

Understanding side effects caused by HER2+ breast cancer treatment

Safety outcomes with first-line treatment of Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) plus Perjeta (pertuzumab) is comparable...
woman scientist examining slide under microscope lab

What is HER2 and why should you get tested? Q&A with Dr. Heidi Ko

Understanding HER2 as a tumor-agnostic biomarker in cancer care and what it means for treatment...
woman relaxing on the couch looking at phone

8 health insurance benefits to claim after breast cancer

8 health insurance benefits to ask for after breast cancer A breast cancer diagnosis doesn’t...
male doctor consulting with an older female patient in office

How do CDK 4/6 inhibitors work for hormone receptor-positive, HER2-negative metastatic breast cancer?

CDK 4/6 inhibitor side effects, treatment length, and more Dr. Pooja Advani is a breast...
DNA test concept, genetic profiling background

ASCO 2025: Enhertu remains efficacious regardless of mutation status in HER2-low, ultra-low metastatic breast cancer

Enhertu (fam-trastuzumab deruxtecan-nxki or T-DXd) has shown promising results in slowing down or stopping the...

Related Pages

Free Cancer Guidance & Support  •  Free Cancer Care Support App  •  Cancer Care Webinars  •  Breast Cancer  •  DCIS Breast Cancer  •  DCIS HER2+ Breast Cancer  •  DCIS HER2- Breast Cancer  •  Non-Metastatic Breast Cancer  •  Non-Metastatic Stage 1 Breast Cancer  •  Non-Metastatic Stage 1 HER2+ Breast Cancer  •  Non-Metastatic Stage 1 HER2 Negative Breast Cancer  •  Non-Metastatic Stage 2 Breast Cancer  •  Non-Metastatic Stage 2 HER2+ Breast Cancer  •  Non-Metastatic Stage 2 HER2 Negative Breast Cancer  •  Non-Metastatic Stage 3 Breast Cancer  •  Non-Metastatic Stage 3 HER2+ Breast Cancer  •  Non-Metastatic Stage 3 HER2 Negative Breast Cancer  •  Metastatic Stage 4 Breast Cancer  •  Metastatic Stage 4 HER2+ Breast Cancer  •  Metastatic Stage 4 HER2 Negative Breast Cancer  •  ER / PR Breast Cancer Parent  •  ER / PR Positive HER2 Positive  •  ER / PR Positive HER2 Negative  •  ER / PR Negative HER2 Positive  •  ER / PR Negative HER2 Negative  •  Menopause and Breast Cancer Parent  •  Premenopausal Breast Cancer  •  Postmenopausal Breast Cancer

Cancer Care Webinars